The current treatment of small cell lung cancer is mainly based on a combination of radiotherapy and chemotherapy.
The chemotherapy regimen varies according to the stage of the tumour. Current studies have shown that combined radiotherapy and chemotherapy are more effective than radiotherapy alone for patients with limited stage, and radiotherapy plays an important role in preventing tumour spread and treating localised tumour foci.
In recent years, immune-targeted drugs and targeted drugs have been approved for the treatment of small cell lung cancer, such as the immune-targeted drug atezolizumab in combination with chemotherapy or durvalumab in combination with chemotherapy can be used for the first-line treatment of small cell lung cancer in the extensive stage; nivolumab, pembrolizumab or anlotinib can be used for the third-line and above small cell lung cancer treatment, etc.